VolitionRx (VNRX) Cash on Hand per Share

VolitionRx Limited (VNRX) is scaling the commercial implementation of its epigenetic IT system for early tumor detection. Diversification through Nu.Q veterinary tests balances revenues, while moderate outsourcing of kit components optimizes costs. Cash per share reflects liquidity management dynamics, where the current status is 0.07, confirming the company's financial resilience against external market shocks.
Comprehensive metric breakdowns and analytics for VolitionRx (VNRX)

A fundamental stress test of a position requires a liquidity analysis to assess the issuer's viability. VolitionRx Limited (VNRX) invests in the commercialization of Nu.Q epigenetic tests for early oncology diagnostics. This metric determines the amount of net cash per share, excluding one-time payments. By analyzing the cash per share history on GURU.Markets, an investor can see the real capital cushion. An upward trend confirms the financial stability of the development, while stagnation signals a risk of underinvestment in growth.